CN102459324B - Casb7439构建体 - Google Patents

Casb7439构建体 Download PDF

Info

Publication number
CN102459324B
CN102459324B CN201080033569.8A CN201080033569A CN102459324B CN 102459324 B CN102459324 B CN 102459324B CN 201080033569 A CN201080033569 A CN 201080033569A CN 102459324 B CN102459324 B CN 102459324B
Authority
CN
China
Prior art keywords
ala
arg
pro
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080033569.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102459324A (zh
Inventor
N.布莱斯
M.哈维
A.皮罗尔盖
C.里瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN102459324A publication Critical patent/CN102459324A/zh
Application granted granted Critical
Publication of CN102459324B publication Critical patent/CN102459324B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080033569.8A 2009-05-27 2010-05-25 Casb7439构建体 Expired - Fee Related CN102459324B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18138009P 2009-05-27 2009-05-27
US61/181380 2009-05-27
US61/181,380 2009-05-27
US22039609P 2009-06-25 2009-06-25
US61/220,396 2009-06-25
US61/220396 2009-06-25
PCT/EP2010/057141 WO2010136443A1 (fr) 2009-05-27 2010-05-25 Produits de recombinaison de casb7439

Publications (2)

Publication Number Publication Date
CN102459324A CN102459324A (zh) 2012-05-16
CN102459324B true CN102459324B (zh) 2014-07-09

Family

ID=42556967

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080033569.8A Expired - Fee Related CN102459324B (zh) 2009-05-27 2010-05-25 Casb7439构建体

Country Status (19)

Country Link
US (1) US8916514B2 (fr)
EP (1) EP2435469A1 (fr)
JP (1) JP2012528106A (fr)
KR (1) KR20120014054A (fr)
CN (1) CN102459324B (fr)
AU (1) AU2010252012A1 (fr)
BR (1) BRPI1012078A2 (fr)
CA (1) CA2763486A1 (fr)
CL (1) CL2011002994A1 (fr)
CO (1) CO6400229A2 (fr)
DO (1) DOP2011000348A (fr)
EA (1) EA020617B1 (fr)
IL (1) IL216351A0 (fr)
MA (1) MA33409B1 (fr)
MX (1) MX2011012623A (fr)
NZ (1) NZ596501A (fr)
PE (1) PE20120400A1 (fr)
SG (1) SG176220A1 (fr)
WO (1) WO2010136443A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400842C (fr) 2000-02-23 2013-01-15 Smithkline Beecham Biologicals S.A. Nouveaux composes
EP2266603B1 (fr) * 2000-10-18 2012-09-12 GlaxoSmithKline Biologicals S.A. Vaccins contre le cancer
US20140171626A1 (en) * 2012-12-19 2014-06-19 Glaxosmithkline Llc Protein purification
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
US20190255165A1 (en) * 2016-09-21 2019-08-22 Amal Therapeutics Sa Fusion Comprising A Cell Penetrating Peptide, A Multi Epitope And A TLR Peptide Agonist For Treatment Of Cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066506A2 (fr) * 2001-02-21 2002-08-29 Glaxosmithkline Biologicals S.A. Nouvelle utilisation
WO2002092627A2 (fr) * 2001-05-16 2002-11-21 Glaxosmithkline Biologicals S.A. Nouvelle utilisation
CN1426421A (zh) * 2000-02-23 2003-06-25 史密丝克莱恩比彻姆生物有限公司 肿瘤特异性动物蛋白
WO2008030559A2 (fr) * 2006-09-08 2008-03-13 Corixa Corporation Procédés, compositions, et kits de détection et de surveillance d'un cancer du colon

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015763A1 (fr) 1992-02-18 1993-08-19 Smithkline Beecham Corporation Polypeptides de vaccination
AU8116494A (en) 1993-11-12 1995-06-13 Kenichi Matsubara Gene signature
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
TR199801531T2 (xx) 1996-02-09 1998-10-21 Smithkline Beecham Biologicals S.A. Zoster vir�s geni ve �r�n�ne kar�� a��lar.
DK1659178T3 (da) 1998-02-05 2010-07-12 Glaxosmithkline Biolog Sa Fremgangsmåde til oprensning eller fremstilling af et MAGE-protein
US6551795B1 (en) 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
DE69933200T2 (de) 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
US6087168A (en) 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
PT1165778E (pt) 1999-03-11 2007-01-31 Glaxosmithkline Biolog Sa Utilizações de polinucleótidos e polipéptidos casb618
AU5788900A (en) 1999-07-07 2001-01-22 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
EP1290217A2 (fr) 2000-02-04 2003-03-12 Aeomica, Inc. Procedes et appareil destines a predire, a confirmer, et a afficher des informations fonctionnelles derivees d'une sequence genomique
US7811574B2 (en) * 2000-02-23 2010-10-12 Glaxosmithkline Biologicals S.A. Tumour-specific animal proteins
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US8039602B2 (en) 2000-10-31 2011-10-18 Ryogen Llc Isolated genomic polynucleotide fragments from the p15 region of chromosome 11
EP1575515A4 (fr) 2002-08-29 2007-08-08 Genentech Inc Polypeptides de type achaete-scute 2 et acides nucleiques codants, methodes de diagnostic et de traitement des tumeurs
GB0700284D0 (en) * 2007-01-08 2007-02-14 Glaxosmithkline Biolog Sa Combination therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1426421A (zh) * 2000-02-23 2003-06-25 史密丝克莱恩比彻姆生物有限公司 肿瘤特异性动物蛋白
WO2002066506A2 (fr) * 2001-02-21 2002-08-29 Glaxosmithkline Biologicals S.A. Nouvelle utilisation
WO2002092627A2 (fr) * 2001-05-16 2002-11-21 Glaxosmithkline Biologicals S.A. Nouvelle utilisation
WO2008030559A2 (fr) * 2006-09-08 2008-03-13 Corixa Corporation Procédés, compositions, et kits de détection et de surveillance d'un cancer du colon

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Achaete-scute like 2(ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia;JUBB A M et al;《Oncogene》;20060630;第25卷(第24期);第3445-3457页 *
JUBB A M et al.Achaete-scute like 2(ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia.《Oncogene》.2006,第25卷(第24期),第3445-3457页.

Also Published As

Publication number Publication date
IL216351A0 (en) 2012-01-31
CN102459324A (zh) 2012-05-16
BRPI1012078A2 (pt) 2019-09-24
CO6400229A2 (es) 2012-03-15
SG176220A1 (en) 2011-12-29
US8916514B2 (en) 2014-12-23
US20120070491A1 (en) 2012-03-22
CA2763486A1 (fr) 2010-12-02
CL2011002994A1 (es) 2012-07-20
WO2010136443A1 (fr) 2010-12-02
EA020617B1 (ru) 2014-12-30
NZ596501A (en) 2013-11-29
PE20120400A1 (es) 2012-05-04
KR20120014054A (ko) 2012-02-15
EP2435469A1 (fr) 2012-04-04
MA33409B1 (fr) 2012-07-03
JP2012528106A (ja) 2012-11-12
AU2010252012A1 (en) 2011-12-22
DOP2011000348A (es) 2012-01-15
MX2011012623A (es) 2011-12-14
EA201190274A1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
CN102459324B (zh) Casb7439构建体
US5869636A (en) Immunoreactive peptide sequence from a 43 kD human cancer antigen
KR20210133888A (ko) 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
KR20090101313A (ko) 백신
HU228467B1 (en) Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
EP2118128B1 (fr) Protéine hybride comprenant les antigènes ny-eso-1 et lage-1
US8309096B2 (en) Fusion protein
US20210236614A1 (en) Vaccine composition and uses thereof
ES2273670T3 (es) Usos de polinucleotidos y polipeptidos casb618.
US7485621B2 (en) Tumor tag and the use thereof
AU2008206463B2 (en) Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1
KR20220040423A (ko) 재조합 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
JP4942906B2 (ja) 卵巣癌の治療および診断のための組成物および方法
CN101583623A (zh) 包含肿瘤排斥抗原ny-eso-1和lage-1的融合蛋白
CA2592156A1 (fr) Vaccins et leur utilisation
JPH11514848A (ja) 黒色腫関連タンパク質

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140709

Termination date: 20170525